NEW YORK (GenomeWeb News) – Affymetrix today said that it has expanded its license agreement with Siemens Healthcare Diagnostics for its branched DNA (bDNA) technology.

The Santa Clara, Calif.-based firm now has exclusive rights to develop and sell in situ QuantiGene ViewRNA products in the in vitro diagnostic market. The products are currently for research-use only. The license also provides Affy exclusive rights to alkaline phosphatase conjugated oligonucleotides and the use of them in bDNA methods for in situ detection using Fast Red substrates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.